Clinical trial
The Combination of ATRA and Eltrombopag as the Treatment Strategy for Glucocorticoid-Resistant/Relapsed ITP Based on the Stratification of the New Biomarker MSC-C5b-9: A Prospective, Randomized, Open-Label, Multicenter Clinical Trial
NCT05438875 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Combination of ATRA and Eltrombopag as the Treatment Strategy for Glucocorticoid-Resistant/Relapsed ITP Based on the Stratification of the New Biomarker MSC-C5b-9: A Prospective, Randomized, Open-Label, Multicenter Clinical Trial
- Lead sponsor
- Peking University People's Hospital
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 12, 2022
- Completion date
- November 30, 2024
- Enrollment
- 96 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.